<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20031029091806</creation_date><modification_date>D:20031029091807+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_w_dec_12.pdf</pdf_file></head><body><section><header>i</header></section><section><header>en</header><p>commission of the european communitiesbrussels, 24/10/2003c(2003) 4006
 not for publication</p></section><section><header>commission decisionof 24/10/2003
 amending decision c(2000)1407 on the marketing authorization for
 the medicinal product for human use
 &quot;pegintron - peginterferon alfa-2b&quot;
  (text with eea relevance)</header><p>only the french and the dutch texts are authentic.ii</p></section><section><header>commission decisionof 24/10/2003
 amending decision c(2000)1407 on the marketing authorization for
 the medicinal product for human use
 &quot;pegintron - peginterferon alfa-2b&quot;
  (text with eea relevance)</header><p>the commission of the european communities,having regard to the treaty establishing the european community,
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down
 community procedures for the authorization and supervision of medicinal products for
 human and veterinary use and establishing a european agency for the evaluation of
 medicinal products
 1, as amended by commission regulation (ec) no 649/982,having regard to commission regulation (ec) no 542/95 of 10 march 1995 concerning
 the examination of variations to the terms of a marketing authorisation falling within the
 scope of council regulation (eec) no 2309/93
 3, as amended by commissionregulation (ec) no 1069/98
 4, and in particular article 8(3) thereof,having regard to the opinion of the european agency for the evaluation of medicinal
 products,
 whereas:
 (1)</p><p>the medicinal product &quot;pegintron - peginterferon alfa-2b&quot; entered in the
 community register of medicinal products under nos eu/1/00/131/001-050
 authorised by commission decision c(2000)1407 of 25 may 2000, as amended,
 complies with the requirements set out in regulation (eec) no 2309/93.
 (2)</p><p>schering plough europe submitted an application on 23 may 2003 pursuant to
 article 6(1) set out in regulation (ec) no 542/95.
 (3)</p><p>the european agency for the evaluation of medicinal products delivered a
 favourable opinion formulated on 24 july 2003 by the committee for proprietary
 medicinal products,
 (4)</p><p>decision c(2000)1407 should therefore be amended accordingly.</p><p> 
 1 oj no l 214, 24. 8. 1993, p. 1.2 oj l 88, 24.3.1998, p. 7.3 oj no l 55, 11.3.1995, p. 154 oj l 153, 27.5.1998, p. 11iii(5)</p><p>the measures provided for in this decision are in accordance with the opinion of
 the standing committee on medicinal products for human use,
 has adopted this decision:
 article 1decision c(2000)1407 is amended as follows:1. annex i is replaced by annex i to this decision;
 2. annex iii (a and b) is replaced by annex ii to this decision.
 article 2this decision is addressed to schering plough europe, rue de stalle, 73, 1180 bruxelles,belgique – stallestraat, 73 – 1180 brussel, belgië.
 done at brussels, 24/10/2003
 for the commissionerkki liikanen
 member of the commission</p></section></body></xml>